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Carnitine deﬁciencyWe report three adult sibs (one female, two males) with symptomatic glutaric acidura type I, who were diag-
nosed after a low carnitine level was found by newborn screening in a healthy newborn of the women. All
three adults had low plasma carnitine, elevated glutaric acid levels and pronounced 3-hydroxyglutaric aciduria.
The diagnosis was conﬁrmed by undetectable glutaryl-CoA dehydrogenase activity in lymphocytes and two
pathogenic heterozygous mutations in the GCDH gene (c.1060ANG, c.1154CNT). These results reinforce the no-
tion that abnormal metabolite levels in newborns may lead to the diagnosis of adult metabolic disease in the
mother and potentially other family members.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Glutaric aciduria type I (GA I, MIM #231670) is an autosomal reces-
sive inborn error of lysine metabolism with an estimated prevalence of
1/100.000 neonates [1]. GA I is caused by mutations in the GCDH gene,
encoding glutaryl-CoA dehydrogenase. The natural course is usually de-
termined by acute encephalopathic crises precipitated by e.g. infections
during infancy or childhood and progressive dystonia. Treatmentwith a
lysine-restricted diet, carnitine supplementation and aggressive emer-
gency treatment has been shown to signiﬁcantly improve outcome in
GA I [2–4]. A small group of untreated GAI patients remains asymptom-
atic, even in adult life [5].
Since 2007, GA I is included in the Dutch newborn screening pro-
gram. In this paper we report a mother and her two brothers with
symptomatic GA I, who were diagnosed after a low carnitine level was
found by newborn screening in the healthy newborn of this mother.1.1. Cases
Patient 1 is a 35 year old Dutch female. Her infancy and childhood
were uneventful with exception of two hospital admissions due to
fainting, for which no causewas detected, in the ﬁrst year of life. She al-
ways had some difﬁculties in performing sports because of exercisedicine 463, Radboud University
he Netherlands. Tel.: +31 24
H. Janssen).
. This is an open access article underintolerance. From age 30 onwards, she complained of increasing and
disabling fatigue andwas diagnosedwith ‘burnout’. She had no intellec-
tual problems or movement disorder.
The pregnancy of her ﬁrst child was uneventful besides excessive fa-
tigue and resulted in delivery of a healthy female newborn at term (birth
weight 3840 g). The total carnitine concentration at day 3 in the new-
born screening blood spot was 9.7 μmol/L (ref 20–55 μmol/L). As we
are aware of maternal carnitine deﬁciency presenting this way, we al-
ways screen the mothers simultaneously. The maternal free (4.6 μmol/L,
ref 20–55 μmol/L) as well as total carnitine levels (6.9 μmol/L, ref 25–
65 μmol/L) in plasma were severely reduced. Additional investigations
demonstrated elevated plasma glutarylcarnitine (1.27 μmol/L,
ref b 0.06 μmol/L), urinary glutaric acid (687 μmol/mmol kreat, ref b 30)
and clearly increased 3-hydroxyglutaric acid. The newborn had no ele-
vated glutarylcarnitine of urinary glutaric acid. Glutaryl-CoA dehydro-
genase activity in lymphocytes was undetectable: b1.0 nmol/h.mg
protein (ref 4.8–20 nmol/h.mg). Mutation analysis of the GCDH gene
revealed two pathogenic heterozygous mutations (c.1060ANG and
c.1154CNT), which proved the diagnosis of GA I. MRI of the brain showed
enlarged sylvian ﬁssures (Fig. 1). ECG and cardiac ultrasound were
normal, especially no cardiomyopathy was detected. Carnitine supple-
mentation was started 660 mg BID with slight improvement of exercise
tolerance. After starting protein-controlled nutrition she felt much better.
Patient 2 is the 33 year old brother of patient 1. During childhood he
was investigated because of macrocephaly and learning difﬁculties. CT
scan of the brain at that time showed no abnormalities besides two
arachnoidal cysts. He was then lost to follow-up until the diagnosis
was made in his sister. At the current age of 33 years he has nothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1.MRI features of patient 1. Fluid attenuated inversion recovery image demonstrating
enlarged sylvian ﬁssures.
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plasma demonstrated low free carnitine (7.7 μmol/L, ref 20–55 μmol/L)
as well as total carnitine (10.6 μmol/L, ref 25–65 μmol/L), elevated
glutarylcarnitine (1.55 μmol/L, ref b0.06 μmol/L) and in urine glutaric-
and 3hydroxy-glutaric aciduria. Glutaryl-CoA dehydrogenase activity
in lymphocytes was b1.0 nmol/h.mg protein (ref 4.8–20 nmol/h.mg
protein). DNA investigations revealed the same two heterozygous mu-
tations as detected in patient 1.
Patient 3, the youngest brother, is 24 years old. He only complains of
intermittent fatigue. He also had a low free (7.5 μmol/L) and total carni-
tine (10.4 μmol/L), elevated glutarylcarnitine in plasma and glutaric
acid and 3hydroxy-glutaric acid in urine, decreased glutaryl-CoA dehy-
drogenase activity in lymphocytes and the same two heterozygous mu-
tations. Fatigue disappeared on carnitine 660 mg BID supplementation.
Evaluation of the healthy parents of the three patients revealed only
a slightly elevated glutarylcarnitine in themother. Nometabolic abnor-
malities were found in the father, both had one heterozygous mutation
in GCDH.2. Discussion
Newborn screening has allowed the early identiﬁcation of patients
with GA I [3] and thereby improved the outcome of affected individuals
[2,5]. Incidentally, maternal GA I is diagnosed based on the ﬁndings in
their offspring. Until now, seven cases of maternal GA I are reported in
the literature [6–10]. There is only one more detailed case description
of amother with a history of hypotonia, macrocephaly, learning disabil-
ities (IQ 75) and a typical MRI [9]. Also two mothers are reported with
intermittent fatigue mitigating on carnitine supplementation [10]. For
the other four cases, no details about the clinical presentation areprovided [5,6]. To the best of our knowledge, in contrast to e.g. maternal
phenylketonuria, maternal glutaric aciduria does not affect the health
and development of the offspring [9]. The child of our patient 1 shows
a normal development during 12 month follow-up.
For the ﬁrst time we present a family of three affected adult family
members identiﬁed by an abnormal newborn screening. Isolated carni-
tine deﬁciencywas found in the unaffected newborn of patient 1, which
lead to the diagnosis of GA I in herself and subsequently in her two
brothers. The identiﬁed mutations have been previously reported [11].
Since the extension of the new born screening in the Netherlands
we, and others, have experienced that low carnitine ascertained during
new born screening can be associated with lowmaternal plasma carni-
tine levels [12]. This ﬁnding can be due to maternal conditions e.g. the
pregnancy itself [12], nutritional state (vegetarian) [13], primary carni-
tine deﬁciency [14,15] or 3-methyl-crotonyl-CoA-carboxylase deﬁcien-
cy [16].
As in most inborn errors of metabolism, the phenotypic spectrum of
GA I is broad. It ranges from severely affected individuals to asymptom-
atic adults [17]. Neurological damage can be prevented with adequate
crisis management and a lysine-restricted diet [2–4]. Inter- and intra-
familial variabilities in clinical presentations are described and raise im-
portant questions in terms of incidence and prevalence, pathogenesis
and patient management. In only a few patients the diagnosis was
made after the age of 18 years [18]. GA I is thought to be rare in adults,
but it has been suggested that there are almost certainly unrecognized
cases among populations of adults with stable neurological deﬁcits ac-
quired in childhood or even with only complaints of fatigue [19,20].
Our patients underline the clinical and neuro-radiological variability
of this disorder. All three patients had the typical metabolites in blood
and urine, including low serum carnitine levels. The latter is due to
years of excretion of excessive levels of glutarylcarnitine. Their clinical
signs and symptoms, however, differed. Patient 1, mother of the unaf-
fected newborn who led to the diagnosis, suffered debilitating fatigue
which improved on carnitine supplementation and a protein restricted
diet. Metabolic decompensation never occurred, not even during the
delivery. She also showed MRI described in patients with GA I before
[21–23]. From her two younger brothers affected, one had no com-
plaints at all and one had intermittent fatigue improving on only carni-
tine supplementation.
Our ﬁndings reinforce two notions. Extended newborn screening
can detect symptomatic maternal disorders or even more affected fam-
ily members with treatable metabolic disorders. Low serum carnitine
levels are a rare, but treatable cause of excessive fatigue.
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